New Cancer Treatment Shows Promise in Tumor Eradication
New shot for cancer can eradicate whole tumors in patients, trial shows - report
Image: Jpost
A new injection called amivantamab has shown remarkable results in shrinking tumors for over one-third of patients in a trial involving 102 individuals with head and neck cancer. Developed by Johnson & Johnson, the treatment could significantly improve survival rates for patients with limited options.
- 01The trial included 102 patients with head and neck cancer, with 43 experiencing tumor size reduction.
- 02Among those, 28 patients saw significant shrinkage, while 15 had complete tumor dissolution.
- 03Patients began noticing changes in tumor size in less than a week after receiving the injection.
- 04Amivantamab targets cancer by blocking growth factor receptors, a pathway for evasion, and activating the immune system.
- 05The treatment could potentially benefit thousands of patients annually, particularly those resistant to standard therapies.
Advertisement
In-Article Ad
A recent trial has revealed that amivantamab, an injection developed by Johnson & Johnson, can effectively eliminate tumors in some patients with head and neck cancer. Out of 102 participants across 11 countries, over one-third experienced a reduction in tumor size, with 28 patients showing significant shrinkage, and 15 achieving complete tumor dissolution. Remarkably, changes were observed in less than a week. This treatment is particularly aimed at patients whose cancer has not responded to other therapies. Those who received the injection had a median survival of one year, despite the challenging prognosis typically associated with this cancer type. Amivantamab operates through three mechanisms: blocking epidermal growth factor receptors, hindering the MET pathway, and stimulating the immune system to target tumors. Experts, including Kevin Harrington from London's Institute of Cancer Research, have highlighted the unprecedented responses observed, noting the potential for this treatment to help thousands of patients each year.
Advertisement
In-Article Ad
The treatment offers hope for patients with limited options, potentially improving survival rates and quality of life.
Advertisement
In-Article Ad
Reader Poll
What do you think about the new cancer treatment amivantamab?
Connecting to poll...
More about Johnson & Johnson

Johnson & Johnson annonce des résultats prometteurs pour son traitement du cancer de la prostate
Investing French • May 31, 2026

L'apalutamide de Johnson & Johnson réduit significativement le risque de décès par cancer de la prostate
Investing French • May 31, 2026

Breakthrough Cancer Treatment Shows Remarkable Efficacy in Global Clinical Trial
The Independent • May 31, 2026
Read the original article
Visit the source for the complete story.
